Reforgene Medicine

Reforgene Medicine, founded in 2019 and based in China, is a groundbreaking player in the biotechnology and healthcare industries. The company's mission revolves around leveraging cutting-edge CRISPR and genomic technologies to develop innovative and transformative medicines that cater to unmet medical needs across various therapeutic areas, including genetic disorders, complex diseases, and oncology. With a comprehensive range of capabilities that encompass proprietary gene-editing platforms, drug discovery pipelines, as well as in vivo and in vitro preclinical models, Reforgene Medicine is committed to advancing accessible and curative therapies. The company recently secured a significant $15.00M Series B investment on 28 April 2023, with a diverse group of investors including Everbright, Alwin Capital, BioTrack Capital, Shanfeng Venture Capital, Guangzhou Yuexiu Industrial Investment Fund, Xinxing Fund, Hong Kong and Guangdong Capital, IFSC, Guangzhou Guoju Venture Capital, and Yuanyin Venture Capital. This substantial investment underscores the confidence of industry players in Reforgene Medicine's potential to drive meaningful advancements in gene-editing therapeutics. With its focus on innovation and commitment to addressing unmet medical needs, Reforgene Medicine is poised to make a significant impact in the biotechnology and healthcare sectors, making it an intriguing prospect for venture capital firms seeking opportunities in cutting-edge medical technologies.